The Michel Sadelain Lab: Publications

Share

Print

Share

Print

Visit PubMed for a full listing of Michel Sadelain’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z, Whitlock BM, Miele MM, Li Z, Cunanan KM, Huse M, Hendrickson RC, Wang X, Rivière I, Sadelain M. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019 Apr;568(7750):112-116.

Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Andreas M, Sadelain M, Einsele H, Hudecek M. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci. Transl. Med. 11, eaau5907 (2019).

Feucht, F., Sun, J., Eyquem, J., Ho, Y., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., Sadelain, M. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine Dec 17, 2018.

June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. 2018 Jul 5;379(1):64-73.

Commentary: Caulley L, Ramaswami R, Longo DL, Phimister EG, Ingelfinger JR, Ropper AH, Stern K, Burke AE, Knoper KM, Seals JJJ, Müller DC, Drazen JM. A Look Forward - The Frontiers in Medicine Series. N Engl J Med. 2018 Jul 5;379(1):85-86.

Giavridis T., van der Stegen S.J.C., Eyquem J., Hamieh M., Piersigilli A., Sadelain M. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature Medicine. Online 28 May 2018. DOI: 10.1038/s41591-018-0041-7.

Commentary: Rooney C., Sauer T. Modeling cytokine release syndrome. Nature Medicine. Online 28 May 2018.

Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1;378(5):449-459.

Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017 May 24;545(7655):423-431.

Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, Gönen M, Sadelain M. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.Nature. 2017 Mar 2;543(7643):113-117.

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Zhao Z, Condomines M, van der Stegen SJ, Perna F, Kloss CC, Gunset G, Plotkin J, Sadelain M. Cancer Cell. 2015 Oct 12;28(4):415-28.

Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014 Nov 5;6(261):261ra151. doi: 10.1126/scitranslmed.3010162.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SC, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He W, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DCG, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Sci Transl Med 19 February 2014. Vol. 6, Issue 224, p. 224ra25. DOI: 10.1126/scitranslmed.3008226.

Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses. Sci Transl Med. 2013 Dec 11;5(215):215ra172. doi: 10.1126/scitranslmed.3006597.

Themeli M, Kloss C, Ciriello G, Fedorov VD, Perna F, Gonen M, Sadelain M. Generation of functional tumor-targeted T lymphocytes from human chimeric antigen receptor-engineered induced pluripotent stem cells. Nat Biotech. 2013 Aug 11.doi: 10.1038/nbt.2678. [Epub ahead of print].